The U.S. Food and Drug Administration will not approve a drug if there is more than a 2.5 percent chance that it doesn’t work—no matter the disease or how poor the prognosis. And in a recently published paper, Massachusetts Institute of Technology finance professor Andrew Lo took the FDA to task for not being more flexible. Jagpreet Chhatwal (Mass General) is quoted.
